Haemostasis impairment in patients with obstructive jaundice

Journal of Gastrointestinal and Liver Diseases

Volumn 16, Issue 2, 2007, Pages 177-186

  Papadopoulos, Vassilios ^a   Filippou, Dimitrios ^b,c,d   Manolis, Evangelos ^b   Mimidis, Konstantinos ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d NONE   (Greece)

Author keywords

Acute pancreatitis; Coagulation; Haemostasis impairment; Hepatocellular carcinoma; Obstructive jaundice; Pancreatic adenocarcinoma; Vitamin K

Indexed keywords

ACTIVATED PROTEIN C; AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN; APROTININ; DROTRECOGIN; THROMBOPLASTIN; TRANEXAMIC ACID; VITAMIN K GROUP;

ACUTE PANCREATITIS; BILE DUCT CARCINOMA; BLEEDING; CHOLESTASIS; CRYOPRECIPITATE; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG MECHANISM; HEMOSTASIS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; NONHUMAN; OBSTRUCTIVE JAUNDICE; PANCREAS ADENOCARCINOMA; PROTHROMBIN TIME; REVIEW; SEPSIS; THROMBOEMBOLISM; THROMBOSIS; VITAMIN K DEFICIENCY;

BLOOD COAGULATION DISORDERS; HUMANS; JAUNDICE, OBSTRUCTIVE;

EID: 34347358727     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Watson SP. Collagen receptor signalling in platelets and megakaryocytes. Thromb Haemost 1999;82:365-376
2. Berndt MC, Shen Y, Dopheide AM, et al. The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost 2001;86:178-188
3. Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors: a dual role for glycoprotein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem 1992; 267:11300-11306
4. Caldwell SH, Chang C, Macik BG. Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in nedd of controlled trials. Hepatology 2004;39:592-8
5. Scott-Conner CEH, Grogan JB. The pathophysiology of biliary obstruction and its effect on phagocytic and immune function. J Surg Res 1994;57:316-36
6. Beckingham IJ, Ryder SD. ABC of diseases of liver, pancreas, and biliary system: Investigation of liver and biliary disease. BMJ 2001;322:33-36
7. Ding JW, Anderson R, Norgren L, Stenram U, Bengmark S. The influence of biliary obstruction and sepsis on reticuloendothelial function in rats. Eur J Surg 1992;158:157-64
8. Kuzu MA, Kale IT, Col C, Tekeli A, Tanik A, Koksoy C. Obstructive jaundice promotes bacterial translocation in humans. Hepatogastroenterology 1999;46:159-64
9. Van Thiel DH, George M, Mindikoglu AL, Baluch MH, Dhillon S. Coagulation and fibrinolysis in individuals with advanced liver disease. Turk J Gastroenterol 2004; 15:67-72
10. Mimidis K, Papadopoulos V, Kotsianidis J, et al. Alterations of platelet function, number and indexes during acute pancreatitis. Pancreatology 2004;4:22-27
11. Mimidis K, Papadopoulos V, Kartasis Z. Assessment of platelet adhesiveness and aggregation in mild acute pancreatitis using the PFA-100 system. JOP 2004;5:132-137
12. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liv Dis 2002;22:83-96
13. Sherlock S. Nutritional complications of biliary cirrhosis. Am J Clin Nutr 1970; 23:640-644
14. O'Brien DP, Shearer MJ, Waldron RP, Horgan PG, Given HF. The extent of vitamin K deficiency in patients with cholestatic jaundice. J R S Med 1994;87:320-322
15. Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 1966;45:645-657
16. Peck-Radosavljevic M, Wichlas M, Zacherl J, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000;95:795-801
17. Goulis J, Chau TN, Jordan S, et al. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999;44:754-758
18. Stockelberg D, Andersson P, Bjornsson E, Bjork S, Wadenvik H. Plasma thrombopoietin levels in liver cirrhosis and kidney failure. J Intern Med 1999;246:471-475
19. Koike Y, Yoneyama A, Shirai J, et al. Evaluation of thrombopoiesis in thrombocytopenic disorders by simultaneous measurement of reticulated platelets of whole blood and serum thrombopoietin concentrations. Thromb Haemost 1998;79:1106-1110
20. Stein SF, Harker LA. Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med 1982;99:217-230
21. Pereira J, Accatino L, Alfaro J, Brahm J, Hidalgo P, Mezzano D. Platelet autoantibodies in patients with chronic liver disease. Am J Hematol 1995;50:173-178
22. Lindenbaum J. Folate and vitamin B12 deficiencies in alcoholism. Semin Hematol 1980;17:119-129
23. Levine RF, Spivak JL, Meagher RC, Sieber F. Effect of ethanol on thrombopoiesis. Br J Haematol 1986;62:345-354
24. Ben Ari Z, Osman E, Hutton RA, Burroughs AK. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol 1999;94:2977-2982.
25. Escolar G, Cases A, Vinas M, et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 1999;84:614-619
26. Laffi G, Cominelli F, Ruggiero M, et al. Altered platelet function in cirrhosis of the liver: impairment of inositol lipid and arachidonic acid metabolism in response to agonists. Hepatology 1988;8:1620-1626
27. Ordinas A, Escolar G, Cirera I, et al. Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: studies under flow conditions. Hepatology 1996;24:1137-1142
28. Laffi G, Marra F, Failli P, et al. Defective signal transduction in platelets from cirrhotics is associated with increased cyclic nucleotides. Gastroenterology 1993;105:148-156
29. Laffi G, Marra F, Gresele P, et al. Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology 1992;103:641-646.
30. Owen JS, Hutton RA, Day RC, Bruckdorfer KR, McIntyre N. Platelet lipid composition and platelet aggregation in human liver disease. J Lipid Res 1981; 22:423-430
31. Guarner C, Soriano G, Such J, et al. Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination. Gastroenterology 1992;102:303-309
32. Albornoz L, Bandi JC, Otaso JC, Laudanno O, Mastai R. Prolonged bleeding time in experimental cirrhosis: role of nitric oxide. J Hepatol 1999;30:456-460
33. Michelson AD, Barnard MR. Plasmin-induced redistribution of platelet glycoprotein Ib. Blood 1990;76:2005-2010
34. Pasche B, Ouimet H, Francis S, Loscalzo J. Structural changes in platelet glycoprotein IIb/IIIa by plasmin: determinants and functional consequences. Blood 1994;83:404-414
35. Turitto VT, Baumgartner HR. Platelet interaction with subendotheliumin a perfusion system: physical role of red blood cells. Microvasc Res 1975;9:335-344
36. Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001;85:667-670
37. Violi F, Ferro D, Basili S, et al. Hyperfibrinolysis resulting from clotting activation in patients with different degree of cirrhosis. Hepatology 1993;17:78-83
38. Car JM. Disseminated intravascular coagulation in cirrhosis. Hepatology 1989; 10:103-110
39. Hersch SL, Kunelis T, Francis RB. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for plasminogen activator inhibitor. Blood 1987;69:1315-1319
40. Papadopoulos V, Kartasis Z, Mimidis K, et al. Evaluation of haemostasis impairment in early stages of liver cirrhosis: a clinical study. HAEMA 2004;7:471-478
41. Belli L, Romani F, Sansalone CV, Aseni P, Rondinara G. Portal thrombosis in cirrhotics. A retrospective analysis. Ann Surg 1986;203:286-291
42. Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005;41:553-558
43. Bosch J, Reverter JC. The coagulopathy in cirrhosis: Myth or reality? Hepatology 2005;41:434-435
44. Takeda ST, Takaki A, Ohsato K. occurrence of disseminated intravascular coagulation (DIC) in obstructive jaundice and its relation to biliary tract infection. Jap J Surg 1977;7:82-89
45. Padillo FJ, Muntane J, Montero JL, et al. Effect of internal biliary drainage on plasma levels of endotoxin, cytokines and C-reactive protein in patients with obstructive jaundiuce. World J Surg 2002;26:1328-1332
46. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000;85:967-972
47. Basili S, Ferro D, Violi F. Endotoxaemia, hyperfibrinolysis and bleeding in cirrhosis. Lancet 1999;353:1102
48. Saliola M, Lorenzet R, Ferro D, et al. Enhanced expression of monocyte TF in patients with liver cirrhosis.Gut 1998;43:428-432
49. Ferro D, Basili S, Pratico D, et al. Vitamin E reduces monocyte TF expression in cirrhotic patients. Blood 1999;93:2945-2950
50. Okajima K, Sakamoto Y, Uchiba M. Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: a study of 204 cases. Am J Hematol 2000;65:215-222
51. Goulis J, Patch D, Burroughs AK. Bacterial infection in the pathogenesis of variceal bleeding. Lancet 1999;353:139-142
52. Amaral A, Opal SM, Vincent JL. Coagulation in sepsis. Intensive Care Med 2004;30:1032-1040
53. Gando S, Nanzaki S, Sasaki S, et al: Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit Care Med 1998; 26:2005-2009
54. Doshi SN, Marmur JD: Evolving role of TF and its pathway inhibitor. Crit Care Med 2002;30:54-59
55. Gando S, Kameue T, Morimoto Y, Matsuda N, Hayakawa M, Kemmotsu O. TF production not balanced by TF pathway inhibitor in septis promotes poor prognosis. Crit Care Med 2002;30:32-41
56. Tapper H, Herwald H. Modulation of hemostatic mechanisms in bacterial infectious diseases. Blood 2000; 96:2329-2337
57. Lopes-Bezzera LM, Filler SG. Endothelial cells, TF and infectious diseases. Braz J Med Biol Res 2003; 36:987-991
58. McVey JH. TF Pathway. Baillere's Clinl Haematol 1999; 12:361-372
59. Riewald M, Ruf W. Orchestration of coagulation protease signaling by TF. TCM 2002; 12:149-154
60. Giessen PLA, Rauch U, Bohrmann B, et al. Blood-borne TF: Another view of thrombosis. Proc Natl Acad Sci U.S.A. 1999; 96:2311-2315
61. Bugge TH, Xiao Q, Kombrinck KW, et al. Fatal embryonic bleeding events in mice lacking TF, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci U.S.A. 1996; 93:6258-6263
62. Bogdanov VY, Balasubramanian V, Hathcock J, et al. Alternatively spliced human TF: a circulating, soluble, thrombogenic protein. Nature Medicine 2003; 9:458-462
63. Semeraro N, Montemurro P, Chetta G, Altomare DF, Giordano D, Colucci M. Increased procoagulant activity of peripheral blood monocytes in human and experimental obstructive jaundice. Gastroenterology 1989;96:892-898
64. Kakkar AK, Lemoine NR, Scully MF et al. TF expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995;82:1101-1104
65. Wojtukiewicz MZ, Rucinska M, Zacharski LR, et al. Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost 2001;86:1416-1420
66. Heinmoller E, Schropp T, Kisker O et al. Tumour cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines. Scand J Gastroenterol 1995;30:1008-1016
67. Scialla SJ, Speckart SF, Haut MJ, Kimball DB. Alterations in platelet surface sialyltransferase activity and platelet aggregation in a group of cancer patients with a high incidence of thrombosis. Cancer Res 1979;39:2031-2035
68. Wahrenbrock M, Borsig L, Le D, et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trusseau syndrome with mucinous adenocarcinomas. J Clin Invest 2003;112:853-862
69. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol 2004;5:655-663
70. Nagornay DM, van Heerden JA, Ilstrup DM, Adson MA. Primary hepatic malignancy: surgical management and determinants of survival. Surgery 1989;106:740
71. Hui CK, Yuen MF, Tso WK, Ng IO, Chan AO, Lai CL. Cholangiocarcinoma in liver cirrhosis. J Gastroenterol Hepatol 2003;18:337
72. Wiwanitkit V. Activated partial thromboplastin time abnormality in patients with cholangiocarcinoma. Clin Appl Thromb Haemost 2004;10:69-71
73. Drin FG, Thomson JM, Dymock IW, et al. Abnormal fibrin polymerisation in liver disease. Br J Haematol 1976;34:427-437
74. Barr RD, et al. Dysfibrinogenemia and liver cell growth. J Clin Pathol 1978;31:89-92
75. Liebman HA, Furie B, Tong M, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-1431
76. Weitz IC, Liebman HA. Des-(-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993;18:990-997
77. Nakao A, Virji A, Karr B, et al. Abnormal prothrombin (desgamma-carboxy prothrombin) in hepatocellular carcinoma. Hepatogastroenterology 1991;38:450-453
78. Tseng CS, Lo HW, Chuang WL, Juan CC, Ker CG. Clinical significance of plasma D-dimer levels and serum VEGF levels in patients with hepatocellular carcinoma. Hepatogastroenterology 2004;51:1454-1458
79. Zacharski LR, Hommann M, Kaufmann R. Rationale for clinical trials of coagulation: reactive drugs in hepatocellular carcinoma. Expert Rev Cardiovasc Ther 2004;2:777-784
80. Akiyama K, Nakamura K, Makino I, et al. Antithrombin III producing hepatocellular carcinoma. Thromb Res 1993;72:193-201
81. Miyamoto Y, Takikawa Y, Lin SD, Sato S, Suzuki K. Apoptotic hepatocellular carcinoma HepG2 cells accelerate blood coagulation. Hepatol Res 2004;29:167-167
82. Blanchard RA, Furie BC, Jorgensen M, et al. Acquired vitamin K dependent carboxylation deficiency in liver disease.N Engl J Med 1981;305:242-248
83. Radenkovic D, Bajec D, Karamarkovic A, et al. Disorders of hemostasis during the surgical management of severe necrotizing pancreatitis. Pancreas 2004;29:152-156
84. Salomone T, Tosi P, Palareti G, Tomassetti P, Migliori M, Guariento A, Saieva C, Raiti C, Romboli M, Gullo L. Coagulative disorders in human acute pancreatitis: role for the D-dimer. Pancreas 2003;26:111-116
85. Moberg L, Johansson H, Lukinius A, et al. Production of TF by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002; 360: 2039-2045
86. Beuneu C, Vosters O, Movahedi B, Remmelink M, Salmon I, Pipeleers D, Pradier O, Goldman M, Verhasselt V. Human Pancreatic Duct Cells Exert TF-Dependent Procoagulant Activity. Diabetes 2004;53:1407-1411
87. Zhou W, Levine BA, Olson MS. Platelet-activating factor: a mediator of pancreatic inflammation during cerulein hyperstimulation. Am J Pathol 1993; 142:1504-1512
88. Emanuelli G, Montrucchio G, Gaia E, Dughera L, Corvetti G, Gubetta L. Experimental acute pancreatitis induced by platelet activating factor in rabbits. Am J Pathol 1989; 134:315-326
89. Johnson GB, Brunn GJ, Platt JL. Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS) - like reactions through Toll-like receptor 4. J Immunol 2004;172:20-24
90. Hirota M, Sugita H, Maeda K, Ichibara A, Ogawa M. The concept of SIRS and severe acute pancreatitis. Nippon Rinsho 2004;62:2128-2136
91. Versteeg HH. TF as an evolutionary conserved cytokine receptor: Implications for inflammation and signal transduction. Semin Hematol 2004; 1(Suppl.1):168-172
92. Price GC, Thompson SA, Kam PCA. TF and TF pathway inhibitor. Anaesthesia 2004;59:483-492
93. Mueller MM, Bomke B, Seifried E. Fresh frozen plasma in patients with disseminated intravascular coagulation or in patients with liver diseases. Thrombosis Res 2002;107:9-17
94. Sallah S, Bobzien W. Bleeding problems in patients with liver disease. Postgrad Med 1999;106:231-237
95. Caldwell SH, Chang C, Macik BG. Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in nedd of controlled trials. Hepatology 2004;39:592-598
96. Parekh SJ. Surgery in patients with liver disease: hematological management. Ind J Gastroenterol 2001;20:104-121